

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-096001	Application No. 10/006,265
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masatsugu Maeda et al.	
		Filing Date December 3, 2001	Group Art Unit 1633

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	6,756,481	06/29/2004	Chirica et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A2	WO 97/07215	02/27/1997	WIPO				
	A3	EP 0931646	07/28/1999	EP				
	A4	WO 00/73451	12/07/2000	WIPO				
	A5	WO 00/75314	12/14/2000	WIPO			English Abstract	
	A6	WO 01/85790	11/15/2001	WIPO				
	A7	EP 1188830	03/20/2002	EP				
	A8	WO 02/29060	04/11/2002	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A9	Abbas et al., Cellular and Molecular Immunology, Second edition, W.B. Saunders Co., Philadelphia, pp. 47-48, 1994.
	A10	Bepler et al., "A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in LOH11A metastasis suppressor region", Genomics 55(2):164-175, 1999.
	A11	Bork et al., "Go hunting in sequence databases but watch out for the traps", Trends in Genetics 12:425-427, 1996.
	A12	Bork, "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle", Genome Research 10:398-400, 2000.
	A13	Cosman, "A new cytokine receptor superfamily", Trends Biochem. Sci. 15:265-270, 1990.
	A14	Cosman, "The Hematopoietin Receptor Superfamily", Cytokine 5:95-106, 1993.
	A15	Donaldson et al., "The murine IL-13 receptor $\alpha 2$: Molecular cloning, characterization, and comparison with murine IL-13 receptor $\alpha 2$ ", The Journal of Immunology 161:2317-2324, 1998.
	A16	Genbank Accession No. AAM44229 (hIL-23R), October 19, 2004.
	A17	GenBank Accession No. AF102051, January 28, 1999.
	A18	Genbank Accession No. AY499342, July 10, 2004.
	A19	Genbank Accession No. NM_139017, August 3, 2005.
	A20	Jabbour et al., "Expression of functional prolactin receptors in non-pregnant human endometrium: janus kinase-2, signal transducer ...". J. Clin. Endocrinol. Metab. 83(7):2545-2553, 1998.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-096001	Application No. 10/006,265
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Masatsugu Maeda et al.	
		Filing Date December 3, 2001	Group Art Unit 1633

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	A21	Matsuno et al., "Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody", Arthritis & Rheumatism 41(11):2014-2021, 1998.
	A22	Matthews et al., "A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations", Cell 65:1143-1152, 1991.
	A23	Miyajima et al., "Cytokine receptors and signal transduction", Annu. Rev. Immunol. 10:295-331, 1992.
	A24	Miyazaki et al., "The integrity of the conserved 'WS motif' common to IL-2 and other cytokine receptors is essential for ligand binding and signal transduction", EMBO J. 10(11):3191-3197, 1991.
	A25	Murakami et al., "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family", Proc. Natl. Acad. Sci. 88:11349-11353, December 1991.
	A26	Nishimoto et al., "Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy", Blood 95(1):56-61 2000.
	A27	Nishimoto et al., "Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study", J. Rheumatology 30(7):1426-1435, 2003.
	A28	Oppmann et al., "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12", Immunity 13:715-725, 2000.
	A29	Parham, et al., "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R", The Journal of Immunology 168:5699-5708, 2002.
	A30	Robb et al., "Structural analysis of the gene encoding the murine interleukin-11 receptor α-chain and a related locus", J. Biol. Chem. 271(23):13754-13761, 1996.
	A31	Saito et al., "Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo", J. Immunology 148(12):4066-4071, 1992.
	A32	Sato et al., "Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth", Cancer Research 53:851-856, 1993.
	A33	Simard et al., "Ontogeny of Growth hormone receptors in human tissues: an immunohistochemical study", Journal of Clinical Endocrinology and Metabolism 81(8):3097-3102, 1996.
	A34	Wells et al., "Hematopoietic receptor complexes", Annu. Rev. Biochem. 65:609-634, 1996.
	A35	Wells, "Additivity of mutational effects in proteins", Biochem. 29:8509-8517, 1990.

Examiner Signature /Anne Marie Wehbe/ (05/15/2008)	Date Considered 05/15/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	